O'Connell Daniel P 4
4 · LogicBio Therapeutics, Inc. · Filed Oct 25, 2018
Insider Transaction Report
Form 4
O'Connell Daniel P
Director
Transactions
- Conversion
Series B Convertible Preferred Stock
2018-10-23−4,352,775→ 0 total(indirect: See Footnote)→ Common Stock (2,279,023 underlying) - Conversion
Common Stock
2018-10-23+2,279,023→ 2,279,023 total(indirect: See Footnote) - Purchase
Common Stock
2018-10-23$10.00/sh+700,000$7,000,000→ 2,979,023 total(indirect: See Footnote)
Footnotes (2)
- [F1]Upon closing of the Issuer's initial public offering, each share of Series B Convertible Preferred Stock automatically converted into 0.5235794 shares of Common Stock without payment or further consideration. There was no expiration date for the Series B Convertible Preferred Stock.
- [F2]The Reporting Person is an investment manager of Arix Bioscience, Inc. Arix Bioscience, Inc. and Arix Bioscience Holdings Limited, the direct beneficial owner of these securities, are each wholly owned subsidiaries of Arix Bioscience plc. The Reporting Person disclaims beneficial ownership, within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of these securities in which the Reporting Person has no pecuniary interest.